Linklaters has advised longstanding client Takeda on the successful disposal of its European antacid products to DOC Pharma. The antacid portfolio includes Riopan, an established antacid brand indicated for the symptomatic treatment of conditions related to gastric acidity. The disposal forms part of Takeda’s ongoing strategy to optimise its portfolio and focus on its core therapeutic areas.
Takeda’s in-house legal team was led by Antonio Toma, Head Global Business Development counsel, and Alessandro Piga, Lead Global Business Development counsel.
The international cross-practice Linklaters team was led by M&A Partners Aisling Zarraga and Nicole Meyer, Commercial Partner Georgie Kon, AFIG Partner Annamaria Mangiaracina and Regulatory Partner Jana Hager.
The transaction was signed in March 2026 and completed at the end of May 2026.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
